TxCell Plans 2016 U.S. Studies In Crohn’s After Addressing Manufacturing Issues
This article was originally published in The Pink Sheet Daily
The French cell therapy company is planning to extend its pivotal Phase II study in Crohn’s disease to the U.S. It is one of the larger studies of a cell therapy to date, evaluating what is thought to be the only cell therapy using regulatory T-lymphocytes.
Register for our free email digests: